Skip to main content
Premium Trial:

Request an Annual Quote

Vermillion Gets OK to Continue Listing on Nasdaq

NEW YORK (GenomeWeb News) – Vermillion said today that a Nasdaq Listing Qualifications Panel has determined the firm’s stock could continue trading on the Nasdaq Capital Market, subject to compliance with a rule governing stockholders’ equity by Sept. 22.
 
According to the Fremont, Calif.-based firm, it is required to maintain stockholders’ equity of at least $2.5 million or comply with one of the alternative listing criteria. Vermillion said that it plans to comply with the panel’s conditions for continued listing on the market, but “there can be no assurance that the company will be able to do so.”
 
Vermillion received a letter from Nasdaq on March 25, which said that the firm was not in compliance with a rule that stipulates companies’ securities must have a market value of at least $35 million to retain listing on the exchange. The letter was the second one sent to Vermillion over a two-month perioid that cautioned the firm was not in compliance with that rule.
 
The rule is one of the alternative listing criteria to the stockholders’ equity rule.
 

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.